<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29510918</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>15</Issue><PubDate><Year>2018</Year><Month>Apr</Month><Day>05</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017.</ArticleTitle><Pagination><StartPage>1921</StartPage><EndPage>1924</EndPage><MedlinePgn>1921-1924</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2018.02.055</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(18)30242-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Afghanistan is one of the remaining wild-poliovirus (WPV) endemic countries. We conducted a seroprevalence survey of anti-poliovirus antibodies in Kandahar Province.</AbstractText><AbstractText Label="METHODS">Children in two age groups (6-11&#x202f;months and 36-48&#x202f;months) visiting Mirwais hospital in Kandahar for minor ailments unrelated to polio were enrolled. After obtaining informed consent, we collected venous blood and conducted neutralization assay to detect poliovirus neutralizing antibodies.</AbstractText><AbstractText Label="RESULTS">A total of 420 children were enrolled and 409/420 (97%) were analysed. Seroprevalence to poliovirus type 1 (PV1) was 97% and 100% in the younger and older age groups respectively; it was 71% and 91% for PV2; 93% and 98% for PV3. Age group (RR&#x202f;=&#x202f;3.6, CI 95%&#x202f;=&#x202f;2.2-5.6) and place of residence outside of Kandahar city (RR&#x202f;=&#x202f;1.8, CI 95%&#x202f;=&#x202f;1.2-2.6) were found to be significant risk factors for seronegativity.</AbstractText><AbstractText Label="CONCLUSIONS">The polio eradication program in Kandahar achieved high serological protection, especially against PV1 and PV3. Lower PV2 seroprevalence in the younger age group is a result of a withdrawal of live type 2 vaccine in 2016 and is expected. Ability to reach all children with poliovirus vaccines is a pre-requisite for achieving poliovirus eradication.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Imtiaz</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Peadiatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland. Electronic address: macho@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamid</LastName><ForeName>Nasir A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Care of Afghan Families (CAF), Afghanistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatti</LastName><ForeName>Zaid S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Department of Peadiatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Deborah D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberste</LastName><ForeName>M Steven</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Shahid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Peadiatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Hasan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Polio Eradication Departments, World Health Organization, Kabul, Afghanistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Roland W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhutta</LastName><ForeName>Zulfiqar A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Department of Peadiatrics and Child Health, Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soofi</LastName><ForeName>Sajid B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Peadiatrics and Child Health, Aga Khan University, Karachi, Pakistan. Electronic address: sajid.soofi@aku.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023321">Poliovirus Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000346" MajorTopicYN="N">Afghanistan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023321" MajorTopicYN="N">Poliovirus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062486" MajorTopicYN="N">Public Health Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Eradication</Keyword><Keyword MajorTopicYN="N">Polio</Keyword><Keyword MajorTopicYN="N">Seroprevalence</Keyword><Keyword MajorTopicYN="N">Titre</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29510918</ArticleId><ArticleId IdType="pmc">PMC5873527</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2018.02.055</ArticleId><ArticleId IdType="pii">S0264-410X(18)30242-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cases of Wild Poliovirus by Country and Year. Available at: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx. [accessed 12/02/2018].</Citation></Reference><Reference><Citation>Centers for Disease C, Prevention. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep 2001; 50:222&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11300627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Cochi SL, Jafari HS, Wassilak SG, Mast EE, Diop OM, et al. Possible eradication of wild poliovirus type 3&#x2013;worldwide, 2012. MMWR Morb Mortal Wkly Rep 2014; 63:1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779498</ArticleId><ArticleId IdType="pubmed">25393222</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales M., Tangermann R.H., Wassilak S.G. Progress toward polio eradication &#x2013; worldwide, 2015&#x2013;2016. MMWR Morb Mortal Wkly Rep. 2016;65:470&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">27171208</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R.W., Platt L., Mach O., Jafari H., Aylward R.B. The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014;210(Suppl 1):S434&#x2013;S438.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316865</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh MA, Makokha F, Hussein AM, Mohamed G, Mach O, Humayun K, et al. Combined use of inactivated and oral poliovirus vaccines in refugee camps and surrounding communities &#x2013; Kenya, December 2013. MMWR Morb Mortal Wkly Rep 2014; 63:237&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584634</ArticleId><ArticleId IdType="pubmed">24647400</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I., Mach O., Habib A., Bhatti Z., Suhag Z., Oberste M.S. Seroprevalence of anti-polio antibodies in children from polio high-risk areas of pakistan: a cross-sectional survey 2015&#x2013;2016. Pediatr Infect Dis J. 2017;36:e230&#x2013;e236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9131303</ArticleId><ArticleId IdType="pubmed">28806355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamage D., Palihawadana P., Mach O., Weldon W.C., Oberste S.M., Sutter R.W. Achieving high seroprevalence against polioviruses in Sri Lanka-Results from a serological survey, 2014. J Epidemiol Glob Health. 2015;5:S67&#x2013;S71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6688167</ArticleId><ArticleId IdType="pubmed">26166424</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliyasu Z., Verma H., Craig K.T., Nwaze E., Ahmad-Shehu A., Jibir B.W. Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria. Vaccine. 2016;34:5125&#x2013;5131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036508</ArticleId><ArticleId IdType="pubmed">27591950</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig K.T., Verma H., Iliyasu Z., Mkanda P., Touray K., Johnson T. Role of serial polio seroprevalence studies in guiding implementation of the polio eradication initiative in Kano, Nigeria: 2011&#x2013;2014. J Infect Dis. 2016;213(Suppl 3):S124&#x2013;S130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818560</ArticleId><ArticleId IdType="pubmed">26908720</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliyasu Z., Nwaze E., Verma H., Mustapha A.O., Weldegebriel G., Gasasira A. Survey of poliovirus antibodies in Kano, Northern Nigeria. Vaccine. 2014;32:1414&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pubmed">24041545</ArticleId></ArticleIdList></Reference><Reference><Citation>IVB/WHO. Data, statistics and graphics. Available at: &lt;http://www.who.int/immunization/monitoring_surveillance/data/en/&gt;. [accessed 10/07/2017].</Citation></Reference><Reference><Citation>Weldon W.C., Oberste M.S., Pallansch M.A. standardized methods for detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio vaccines: WHO position paper &#x2013; March, 2016. Wkly Epidemiol Rec 2016; 91:145-68.</Citation><ArticleIdList><ArticleId IdType="pubmed">27039410</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S., Tejeda A., Sutter R.W., Diaz M., Sarmiento L., Alemani N. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368:416&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">23363495</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>